Journal
ACS INFECTIOUS DISEASES
Volume 7, Issue 10, Pages 2764-2776Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.1c00322
Keywords
malaria; Plasmodium; drug discovery; molecular targets
Categories
Funding
- Bill & Melinda Gates Foundation [OPP1054480, OPP1193840, OPP1202973, OPP1032548]
- Medicines for Malaria Venture
- Wellcome [203134/Z/16/Z]
- Wellcome Trust [203134/Z/16/Z] Funding Source: Wellcome Trust
- Bill and Melinda Gates Foundation [OPP1193840, OPP1202973, OPP1032548] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
This paper discusses the important criteria for selecting drug targets in antimalarial drug discovery, as well as the analysis of several drug targets in the MaIDA pipeline. Prioritizing targets ready to enter the drug discovery process can increase the likelihood of progressible drug candidates.
There is a shift in antimalarial drug discovery from phenotypic screening toward target-based approaches, as more potential drug targets are being validated in Plasmodium species. Given the high attrition rate and high cost of drug discovery, it is important to select the targets most likely to deliver progressible drug candidates. In this paper, we describe the criteria that we consider important for selecting targets for antimalarial drug discovery. We describe the analysis of a number of drug targets in the Malaria Drug Accelerator (MaIDA) pipeline, which has allowed us to prioritize targets that are ready to enter the drug discovery process. This selection process has also highlighted where additional data are required to inform target progression or deprioritization of other targets. Finally, we comment on how additional drug targets may be identified.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available